Literature DB >> 35114134

Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose.

Courtney Lawhn-Heath1, Thomas A Hope2, Juana Martinez3, Edward K Fung3, Jaehoon Shin1, Youngho Seo4, Robert R Flavell5.   

Abstract

Radionuclide therapy is a rapidly expanding oncological treatment method. Overwhelmingly, the application of radionuclide therapy in clinical practice relies on fixed or empirical dosing strategies. In principle, the application of dosimetry promises to improve patient outcomes by tailoring administered radionuclide therapy activities to each patient's unique tumour burden and tumour uptake. However, robust prospective data are scarce due to few prospective randomised clinical trials investigating the use of dosimetry in radionuclide therapy. In this Review, we describe the role of dosimetry as it has been applied historically and in modern clinical practice and its potential future applications. We further emphasise areas of future growth and a potential pathway to optimised personalised activity modulation of radionuclide therapy.
Copyright © 2022 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35114134     DOI: 10.1016/S1470-2045(21)00657-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  4 in total

Review 1.  Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?

Authors:  Thomas A Hope; Marianne Pavel; Emily K Bergsland
Journal:  J Clin Oncol       Date:  2022-06-01       Impact factor: 50.717

2.  Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy.

Authors:  Oscar Ardenfors; Joachim N Nilsson; Daniel Thor; Cecilia Hindorf
Journal:  EJNMMI Phys       Date:  2022-06-20

3.  A mesh-based model of liver vasculature: implications for improved radiation dosimetry to liver parenchyma for radiopharmaceuticals.

Authors:  Camilo M Correa-Alfonso; Julia D Withrow; Sean J Domal; Shu Xing; Jungwook Shin; Clemens Grassberger; Harald Paganetti; Wesley E Bolch
Journal:  EJNMMI Phys       Date:  2022-04-13

Review 4.  A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer.

Authors:  Ephraim E Parent; Adam M Kase
Journal:  Cancers (Basel)       Date:  2022-09-01       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.